38177100|t|Screens in aging-relevant human ALS-motor neurons identify MAP4Ks as therapeutic targets for the disease.
38177100|a|Effective therapeutics is much needed for amyotrophic lateral sclerosis (ALS), an adult-onset neurodegenerative disease mainly affecting motor neurons. By screening chemical compounds in human patient-derived and aging-relevant motor neurons, we identify a neuroprotective compound and show that MAP4Ks may serve as therapeutic targets for treating ALS. The lead compound broadly improves survival and function of motor neurons directly converted from human ALS patients. Mechanistically, it works as an inhibitor of MAP4Ks, regulates the MAP4Ks-HDAC6-TUBA4A-RANGAP1 pathway, and normalizes subcellular distribution of RANGAP1 and TDP-43. Finally, in an ALS mouse model we show that inhibiting MAP4Ks preserves motor neurons and significantly extends animal lifespan.
38177100	26	31	human	Species	9606
38177100	32	35	ALS	Disease	MESH:D000690
38177100	148	177	amyotrophic lateral sclerosis	Disease	MESH:D000690
38177100	179	182	ALS	Disease	MESH:D000690
38177100	200	225	neurodegenerative disease	Disease	MESH:D019636
38177100	293	298	human	Species	9606
38177100	299	306	patient	Species	9606
38177100	455	458	ALS	Disease	MESH:D000690
38177100	558	563	human	Species	9606
38177100	564	567	ALS	Disease	MESH:D000690
38177100	568	576	patients	Species	9606
38177100	652	657	HDAC6	Gene	10013
38177100	658	664	TUBA4A	Gene	7277
38177100	665	672	RANGAP1	Gene	5905
38177100	725	732	RANGAP1	Gene	5905
38177100	737	743	TDP-43	Gene	23435
38177100	760	763	ALS	Disease	MESH:D000690
38177100	764	769	mouse	Species	10090
38177100	Association	5905	7277

